Gapping up
In reaction to strong earnings/guidance:
- BYND +28.4%, ZUMZ +15.2%, ZM +14.9%, MTN +6.6%, PD +5.1%, GES +2.7%
M&A news:
- BKS +10.2% (to be acquired by Elliott Advisors for $6.50/share in cash, or approximately $683 mln)
- CZR +6.2% (said near deal to merge with Eldorado Resorts (ERI), according to the WSJ; The NYPost is also out with a story suggesting that the company rejected a roughly $10.50/share bid from ERI, but that the two sides could agree on and announce a new deal next week)
Other news:
- SENS +19.9% (announces FDA approval for non-adjunctive indication for Eversense 90-day Continuous Glucose Monitoring System)
- NEPT +14.6% (to provide extraction, and purification services to Tilray (TLRY))
- CRSP +12.8% (Vertex Pharma expands collaboration with CRISPR Therapeutics; also acquires Exionics Therapeutics for $245 mln)
- LJPC +6.1% (after surging more than 90% higher yesterday)
- SNY +5.9% (appoints Paul Hudson as CEO, succeeding Olivier Brandicourt who has decided to retire)
- ELGX +4.8% (announces reinstatement of CE Mark for Nellix EndoVascular Aneurysm Sealing System)
- HOME +4% (modestly rebounding from yesterday's 57% decline)
- SB +2.8% (announces authorization of 5.0 mln share common stock repurchase program)
- TXMD +2.8% (entered into an exclusive license and supply agreement with Theramex and IMVEXXY outside of the United States)
- TUSK +2.3% (issues statement regarding work in Puerto Rico)
- PSEC +0.9% (Director Sanghi bought 20K shares worth ~$2.2 mln)
Analyst comments:
- PLAN +3% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- AYX +3% (initiated with a Buy at Goldman)
- WTRH +2.7% (initiated with a Buy at Deutsche Bank)
- ZEN +1.7% (initiated with a Buy at Goldman)
- HUBS +1.2% (initiated with a Buy at Goldman)